senior
author
marku
maeurer
epitop
map
receptorbind
domain
influenza
haemagglutinin
could
serv
correl
immun
protect
context
pandem
flu
studi
show
unbias
epitop
map
use
peptid
microarray
technolog
lead
identif
biolog
clinic
relev
target
structur
significantli
infect
induc
differ
footprint
igg
epitop
recognit
pattern
compar
pandem
vaccin
high
content
peptid
microarray
contain
entir
influenza
viru
proteom
haemagglutinin
protein
influenza
subtyp
includ
haemagglutinin
asouth
strain
use
gaug
serum
igg
epitop
signatur
pandemrix
vaccin
infect
swedish
cohort
pandem
influenza
season
narrow
pattern
pandem
fluspecif
igg
epitop
recognit
observ
serum
individu
later
contract
infect
moreov
pandem
influenza
infect
gener
igg
reactiv
two
adjac
epitop
neuraminidas
protein
differenti
serum
igg
recognit
focus
haemagglutinin
restrict
classic
antigen
site
cb
vaccin
control
individu
flu
infect
identifi
novel
epitop
vepgdkitfeatgnl
ca
antigen
site
pandem
flu
haemagglutinin
exclus
recogn
serum
individu
previou
vaccin
never
serum
individu
infect
confirm
rna
pcr
analysi
nasal
swab
influenza
pandem
caus
novel
tripl
reassort
swine
origin
influenza
viru
first
identifi
usa
european
centr
diseas
control
estim
laboratori
confirm
death
case
report
europ
first
year
season
influenza
vaccin
either
adjuv
nonadjuv
exhibit
protect
effect
measur
haemagglutinin
ha
inhibit
assay
young
adult
children
although
individu
born
show
protect
serum
igg
titr
lack
preexist
neutral
antibodi
pandem
influenza
viru
increas
suscept
gener
popul
bcell
epitop
conserv
pandem
swineorigin
influenza
viru
strain
compar
season
variant
flu
strain
moreov
eight
conserv
epitop
singl
epitop
ha
ha
ectodomain
homotrimer
complex
four
distinct
antigen
site
two
polypeptid
chain
homotrim
compris
larg
globular
head
bind
glycan
receptor
distal
stem
region
haemagglutinin
target
neutral
antibodi
context
pandem
influenza
often
describ
immunogenicitydefin
surfac
protein
influenza
virus
therefor
map
studi
serum
igg
epitop
recognit
profil
natur
pandem
flu
infect
pandemrix
vaccin
use
high
content
influenza
peptid
microarray
serum
antibodybas
protein
target
identif
serex
use
success
identifi
number
biolog
relev
target
cancer
show
differ
epitop
recognit
pattern
cours
hiv
infect
versu
hiv
vaccin
choos
similar
approach
defin
epitop
recognit
pattern
serum
use
synthet
linear
peptid
stretch
defin
immun
recognit
pattern
segreg
individu
high
risk
infect
influenza
viru
ii
differ
igg
recognit
pattern
induc
vaccin
versu
infect
iii
share
epitop
recognit
pattern
compar
differ
ha
protein
influenza
strain
includ
ha
pandem
strain
influenza
viru
asouth
immunolog
differ
timepoint
eg
beforeaft
flu
vaccin
differ
patient
group
assay
elisa
use
method
increas
titr
reactiv
differ
target
could
measur
howev
recognit
recombin
protein
elisa
usual
repres
recognit
differ
epitop
linear
conform
peptid
array
screen
feasibl
way
map
differ
humor
immun
respons
though
import
limit
may
exclus
conform
epitop
describ
recent
report
epitopemap
analysi
possibl
current
studi
use
materi
prospect
studi
individu
follow
vaccin
infect
peptid
array
custom
manufactur
jpt
berlin
germani
manufactur
process
base
spot
synthesi
describ
elsewher
use
assay
detail
flu
epitop
recognit
pattern
serum
sampl
ageand
sexmatch
individu
vaccin
adjuv
vaccin
pandem
influenza
pandemrix
use
control
see
fig
region
ethic
committe
stockholm
approv
studi
serum
dilut
buffer
pb
fetal
calf
serum
tween
sigma
aldrich
st
loui
mo
incub
microarray
hr
humid
chamber
slide
wash
buffer
twice
steril
distil
water
thrice
follow
secondari
incub
dilut
monoclon
label
mous
antihuman
igg
antibodi
cat
lot
mgml
southern
biotech
birmingham
al
hour
room
temperatur
wash
slide
spun
dri
slide
centrifug
djb
labcar
newport
pagnel
uk
scan
nm
use
axon
scanner
molecular
devic
sunnyval
ca
imag
analysi
perform
use
circular
featur
align
genepix
pro
softwar
molecular
devic
genepix
array
list
gal
file
suppli
jpt
berlin
germani
slide
analys
use
genepix
imag
analysi
softwar
molecular
devic
gal
file
contain
peptid
inform
spot
suppli
manufactur
jpt
berlin
germani
detect
spot
intern
uniform
flag
bad
ie
unreli
effici
estim
follow
criterion
describ
detail
elsewher
identifi
spot
mean
foreground
valu
differ
spot
exhibit
median
fluoresc
intens
valu
spot
visual
inspect
flag
result
save
separ
subarray
posit
control
spot
subarray
select
care
screen
describ
previous
two
pair
strategi
adopt
context
differenti
recognit
epitop
ie
peptid
exhibit
statist
differ
recognit
immunoglobulin
present
test
group
compar
control
group
strong
recognit
one
group
versu
weak
recognit
group
well
exclus
recognit
peptid
target
recogn
defin
threshold
detect
serum
test
group
never
control
group
vice
versa
epitop
map
crystal
structur
influenza
viru
ha
pdb
ha
receptorbind
domain
pdb
id
perform
use
protein
databank
jmol
opensourc
java
viewer
chemic
structur
use
threedimension
applic
http
wwwjmolorg
monospecif
antibodi
product
neutral
assay
polyclon
monospecif
rabbit
antibodi
specif
vepgdkitfeatgnl
prepar
genscript
piscataway
nj
specif
verifi
indirect
elisa
data
shown
peptidespecif
polyclon
reagent
prepar
three
differ
rabbit
affinitypurifi
use
immobil
vepgdkitfeatgnl
peptid
attach
linker
affinitypurifi
reagent
show
crossreact
nonrelev
peptid
target
three
antibodi
reagent
individu
use
neutral
experi
molecular
epidemiolog
laboratori
univers
siena
perform
viru
neutral
assay
use
cytopath
effect
readout
influenza
viru
previous
describ
affinitypurifi
monospecif
antibodi
heatinactiv
min
serial
twofold
dilut
start
dilut
incub
hr
tcid
influenza
live
viru
equal
volumewel
incub
monospecif
antibodi
viru
allow
neutral
viru
specif
antibodi
mixtur
ad
confluent
monolay
mdck
madin
darbin
canin
kidney
suscept
cell
flatbottom
microtitr
plate
plate
incub
co
day
allow
infect
cell
substrat
case
live
viru
neutral
serum
antibodi
cytopath
effect
monitor
everi
day
end
incub
period
well
microtitr
plate
check
optic
microscop
presenc
cytopath
effect
cell
lawn
compar
neg
posit
control
viru
neutral
titr
defin
antibodi
dilut
mean
well
protect
virusinduc
cytopath
effect
arber
formula
use
calcul
viru
neutral
titr
sampl
data
preprocess
qualiti
control
background
subtract
outlier
fals
posit
detect
remov
normal
previous
describ
differenti
recognit
estim
use
signific
analysi
microarray
nonparametr
penal
ttest
microarray
exclus
recognit
perform
fix
threshold
detect
correspond
averag
respons
neg
control
standard
deviat
count
number
detect
hit
among
case
peptid
level
recognit
alway
valu
control
number
hit
report
togeth
averag
recognit
procedur
perform
use
inhousemad
r
script
packag
project
bioconductor
wwwbioconductororg
differenti
epitopeserum
igg
recognit
pattern
segreg
cluster
base
pandem
influenza
infect
pandemrix
vaccin
serum
individu
test
igg
recognit
use
influenza
peptid
microarray
platform
serum
igg
epitop
reactiv
individu
infect
compar
serum
reactiv
sexand
agematch
individu
pandemrix
vaccin
prospect
studi
cohort
peptid
recogn
differenti
p
group
flu
infect
versu
vaccin
signific
analysi
microarray
method
identifi
repres
fold
chang
tabl
fig
data
present
number
time
particular
epitop
group
experienc
infect
recogn
compar
vaccin
group
onefold
chang
indic
higher
respons
vaccin
group
epitopeserum
igg
recognit
pattern
segreg
cluster
base
group
ie
individu
later
contract
flu
infect
versu
group
receiv
vaccin
see
fig
prospect
studi
design
allow
character
serum
reactiv
vaccin
well
pandem
infect
identifi
cluster
epitop
differenti
recogn
prevaccinationinfect
cluster
epitop
differenti
recogn
postvaccinationinfect
repres
heat
map
fig
flu
season
onset
peptid
epitop
differenti
recogn
group
later
experienc
infect
base
strong
serum
recognit
pattern
defin
fluoresc
intens
two
epitop
pandem
flu
strain
recogn
ie
polymeras
pa
grdrimawtvvns
neuraminidas
nfsikqdivginew
contrast
serum
reactiv
pattern
individu
chose
vaccin
total
epitop
differenti
recogn
epitop
pandem
strain
six
polymeras
pa
two
one
polymeras
one
epitop
ha
vepgdkitfeatgnl
exhaust
list
tabl
flu
season
epitop
segreg
best
vaccin
versu
fluinfect
individu
see
exhaust
list
tabl
tabl
tabl
contrast
serum
vaccin
individu
exhibit
serum
igg
also
cb
epitop
amino
acid
ha
includ
gwllgnpecdlllta
influenza
viru
asouth
spanish
flu
list
support
inform
tabl
novel
epitop
antigen
site
pandem
flu
ha
exclus
recogn
serum
vaccin
individu
exclus
recognit
analysi
perform
ie
whether
epitop
recogn
strongli
exclus
one
group
flu
infect
never
alway
set
cutoff
anoth
group
flu
vaccin
vice
versa
tabl
identifi
epitop
vepgdkitfeatgnl
pandem
flu
ha
exclus
recogn
serum
vaccin
individu
flu
season
individu
also
found
true
postflu
fig
vepgdkitfeatgnl
epitop
pandem
amino
acid
exclus
recogn
serum
control
individu
vaccin
test
whether
polyclon
rabbit
peptideaffin
purifi
monospecif
antibodi
could
neutral
viru
vitro
monospecif
affinitypurifi
antibodi
prepar
n
show
neutral
titr
except
hyperimmun
sheep
serum
test
assay
posit
control
data
shown
demonstr
epitopespecif
antibodi
recogn
neutral
flu
live
viru
test
appli
current
report
aim
studi
character
serumigg
epitop
recognit
profil
cours
natur
pandem
influenza
infect
pandemrix
vaccin
use
highcont
influenza
peptid
microarray
one
salient
find
preexist
serum
igg
pandem
ha
vaccin
individu
onset
flu
season
probabl
due
past
exposur
previou
vaccin
interview
studi
particip
show
individu
chose
vaccin
previous
vice
versa
preexist
serum
igg
result
previou
flu
vaccin
also
preexist
protect
antibodi
past
exposur
strain
may
contribut
humor
respons
broader
pandem
flu
epitop
recognit
pattern
reflect
share
pandem
influenza
epitop
serum
individu
flu
season
onset
well
seven
epitop
pandem
flu
intern
protein
serum
individu
chose
vaccin
biolog
role
antibodi
direct
intern
protein
clear
previou
report
suggest
nonneutr
antibodi
may
decreas
morbid
lead
increas
viral
clearanc
bind
fc
receptor
subsequ
cell
conserv
influenza
intern
protein
may
therefor
help
elicit
memori
b
cell
longliv
contribut
heterosubtyp
immun
antigen
drift
crossprotect
induc
antibodi
gener
reactiv
pandem
describ
previous
subtyp
moreov
absenc
neutral
ha
antibodi
neuraminidasespecif
antibodi
would
instrument
mount
protect
immun
respons
pandem
viru
note
observ
serum
current
cohort
increas
neuraminidas
epitop
reactiv
pandem
epitop
commonli
recogn
could
relat
fact
test
reactiv
linear
epitop
caveat
chip
design
use
current
studi
biolog
relev
conform
epitop
may
miss
antibodi
swine
influenza
viru
found
neutral
pandem
flu
experiment
model
howev
nonneutr
antibodi
produc
swine
origin
past
exposurescould
enhanc
viru
fusion
promot
infect
significantli
subject
current
studi
experienc
infect
confirm
posit
pcr
exhibit
increas
level
igg
sryskkfkpeiaarp
ha
influenza
viru
highli
homolog
sryskkfkpeiairp
epitop
ha
influenza
viru
ha
receptor
bind
domain
singl
amino
acid
mutat
antigen
site
abl
gener
new
epidem
strain
possibl
misdirect
reactiv
lead
symptomat
flu
infect
pandem
ha
exhibit
conserv
epitop
antigen
site
cb
sa
sb
compar
ha
spanish
flu
yet
signific
differ
describ
ca
antigen
site
igg
serum
reactiv
vaccin
individu
gwllgnpecdlllta
antigen
site
cb
direct
vestigi
esteras
domain
influenza
viru
asouth
spanish
flu
epitop
gwllgnpecdlllta
ha
spanish
flu
recogn
serum
immunoglobulin
preand
postvaccin
timepoint
see
support
inform
tabl
support
notion
igg
spanish
flu
may
abl
induc
crossprotect
pandem
flu
addit
serum
individu
also
exhibit
igg
reactiv
direct
nonconserv
ca
site
vepgdkitfeatgnl
pandem
data
show
serum
individu
chose
vaccin
exhibit
strong
preexist
igg
reactiv
toward
pandem
flu
epitop
particularli
pandem
flu
ha
epitop
vepgdkitfeatgnl
reactiv
complet
absent
iggepitop
recognit
repertoir
fluinfect
individu
flu
season
like
epitop
top
two
peptid
epitop
strongli
recogn
serum
individu
beforeaft
pandemrix
vaccin
alway
cutoff
sera
individu
beforeaft
pandem
flu
infect
note
epitop
vepgdkitfeatgnl
pandem
flu
exclus
recogn
serum
individu
pandemrix
vaccin
yet
never
serum
individu
experienc
later
infect
rabbit
monospecif
antibodi
direct
epitop
prepar
neutral
pandem
flu
vitro
function
signific
epitop
could
establish
possibl
explan
linear
peptid
use
immun
rabbit
resembl
fold
epitop
within
nativ
protein
howev
antibodi
detect
serum
vaccin
individu
epitop
may
activ
complement
subsequ
contribut
viru
neutral
biolog
system
test
beyond
scope
studi
sinc
epitopespecif
complementactiv
human
reagent
avail
futur
experi
also
need
address
whether
highavid
antibodi
fluprotect
individu
identifi
peptid
microarray
assay
whether
target
epitop
could
use
guid
vaccin
develop
although
current
studi
may
limit
igg
direct
linear
epitop
could
character
conform
epitop
miss
distinct
igg
recognit
pattern
identifi
pattern
segreg
base
infect
vaccin
could
clearli
link
clinic
relev
endpoint
flu
infect
lead
differ
array
epitop
recognit
compar
flu
vaccin
immun
profil
individu
protect
infecti
pathogen
may
help
tailor
new
vaccin
candid
help
identifi
clinic
relev
marker
immun
protect
addit
support
inform
may
found
onlin
version
articl
tabl
differenti
recogn
epitop
serum
igg
individu
n
later
experienc
pandem
flu
infect
compar
epitop
recogn
serum
igg
individu
n
pandemrix
vaccin
tabl
differenti
recogn
epitop
serum
igg
individu
n
post
pandem
flu
infect
compar
epitop
recogn
serum
igg
individu
n
pandemrix
vaccin
month
valu
present
fold
chang
